Literature DB >> 15090814

Serological pattern 'anti-hepatitis B core alone' in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants.

Anne A Wagner1, François Denis, Pierre Weinbreck, Véronique Loustaud, François Autofage, Sylvie Rogez, Sophie Alain.   

Abstract

We determined the frequency of hepatitis B virus (HBV) occult infection and studied S gene mutations in HIV or hepatitis C virus-co-infected patients with persistent pattern 'anti-hepatitis B core alone'. HBV DNA was particularly frequent in HIV-positive patients. Sequencing of the S gene showed that only two HIV-infected patients harboured mutants in the major hydrophilic loop; the absence of hepatitis B surface antigen detection could not be explained by diagnostic escape mutants.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15090814     DOI: 10.1097/00002030-200402200-00028

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

1.  Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features.

Authors:  G Morsica; F Ancarani; S Bagaglio; M Maracci; P Cicconi; A Cozzi Lepri; G Antonucci; R Bruno; T Santantonio; L Tacconi; F Baldelli; R Piscopo; D Santoro; A Lazzarin; A D'Arminio Monforte
Journal:  Infection       Date:  2009-08-07       Impact factor: 3.553

2.  Double hepatitis B virus infection in a patient with HIV/hepatitis C virus coinfection and 'anti-HBc alone' as serological pattern.

Authors:  A A Wagner; V Loustaud-Ratti; I Chemin; P Weinbreck; F Denis; S Alain
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-09       Impact factor: 3.267

3.  Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients.

Authors:  Stefan Reuter; Mark Oette; Frank Clemens Wilhelm; Bastian Beggel; Rolf Kaiser; Melanie Balduin; Finja Schweitzer; Jens Verheyen; Ortwin Adams; Thomas Lengauer; Gerd Fätkenheuer; Herbert Pfister; Dieter Häussinger
Journal:  Med Microbiol Immunol       Date:  2010-09-19       Impact factor: 3.402

Review 4.  Prevalence of occult hepatitis B virus infection.

Authors:  Maria Luisa Gutiérrez-García; Conrado M Fernandez-Rodriguez; Jose Luis Lledo-Navarro; Ingrid Buhigas-Garcia
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

5.  Genomic variability associated with the presence of occult hepatitis B virus in HIV co-infected individuals.

Authors:  C M Martin; J A Welge; N J Shire; S D Rouster; M T Shata; K E Sherman; J T Blackard
Journal:  J Viral Hepat       Date:  2009-11-02       Impact factor: 3.728

6.  Mutations associated with occult hepatitis B in HIV-positive South Africans.

Authors:  Eleanor A Powell; Maemu P Gededzha; Michael Rentz; Nare J Rakgole; Selokela G Selabe; Tebogo A Seleise; M Jeffrey Mphahlele; Jason T Blackard
Journal:  J Med Virol       Date:  2014-08-27       Impact factor: 2.327

7.  Decreased antigenicity profiles of immune-escaped and drug-resistant hepatitis B surface antigen (HBsAg) double mutants.

Authors:  Mingshun Zhang; Guohong Ge; Yonglin Yang; Xubing Cai; Qiang Fu; Jie Cai; Zuhu Huang
Journal:  Virol J       Date:  2013-09-22       Impact factor: 4.099

8.  Occult Hepatitis B (OBH) in Clinical Settings.

Authors:  Seyed Moayed Alavian; Seyed Mohammad Miri; F Blaine Hollinger; Seyed Mohammad Jazayeri
Journal:  Hepat Mon       Date:  2012-08-25       Impact factor: 0.660

9.  The intracellular HBV DNAs as novel and sensitive biomarkers for the clinical diagnosis of occult HBV infection in HBeAg negative hepatocellular carcinoma in China.

Authors:  Hui Wang; Meng Fang; Xing Gu; Qiang Ji; Dongdi Li; Shu-Qun Cheng; Feng Shen; Chun-Fang Gao
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

Review 10.  Isolated Anti-HBc: Significance and Management.

Authors:  Florian Moretto; François-Xavier Catherine; Clémentine Esteve; Mathieu Blot; Lionel Piroth
Journal:  J Clin Med       Date:  2020-01-11       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.